Aldeyra Plans Quick Response To FDA’s CRL For Reproxalap

 
• By Joseph Haas
  
Dry eye disease
Aldeyra hopes it can quickly refile its NDA for dry eye disease • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip